Generalized Anxiety Disorder Market Insights and Forecast to 2036
A new report analyzes the market for Generalized Anxiety Disorder (GAD), including epidemiology and treatment trends through 2036. It highlights limitations in current therapies and the need for novel drug development.
ResearchAndMarkets.com has released a comprehensive report detailing market insights, epidemiology, and forecasts for Generalized Anxiety Disorder (GAD) up to 2036.
The report indicates that the global burden of GAD remains substantial, often accompanied by high comorbidity rates with conditions like depression, impacting quality of life and healthcare utilization.
Current first-line treatments, including SSRIs, SNRIs, and Cognitive Behavioral Therapy (CBT), are discussed. However, the report identifies persistent limitations such as delayed onset of action, partial response, and risk of relapse, underscoring the need for therapeutic innovation.
The GAD pipeline shows a focus on novel mechanisms beyond traditional monoaminergic systems. Emerging assets mentioned include Definium Therapeutics' DT120 ODT, Sumitomo Pharma/Otsuka's Ulotaront, and Seaport Therapeutics' SPT-320, which are expected to address unmet needs.
The GAD market is projected to experience significant growth by 2036, driven by increasing prevalence and advancements in treatment options. Detailed market size assessments and growth rate projections across key regions are provided within the report.